Bausch Health beats earnings and revenue estimates, remains key player in industry

From Nasdaq: 2025-02-19 19:25:02

Bausch Health (BHC) reported quarterly earnings of $1.21 per share, beating expectations. The company’s revenue for the quarter ended December 2024 was $2.56 billion, exceeding estimates. Despite a 21.1% stock decline this year, Bausch remains a key player in the Medical – Generic Drugs industry. Investors are eager to see future performance.

Personalis (PSNL), another player in the industry, is set to release its quarterly results on February 27. Analysts expect a quarterly loss of $0.25 per share, with a 14.7% decrease in revenues compared to last year. The company’s performance will influence industry trends and investor decisions moving forward.

Investors are looking for guidance on whether to invest in Bausch Health Cos Inc. (BHC). With mixed estimate revisions and a Zacks Rank #3 (Hold), the stock’s future performance remains uncertain. Understanding industry trends and earnings outlook will be crucial in making informed investment decisions in the coming months.



Read more at Nasdaq: Bausch Health (BHC) Q4 Earnings and Revenues Top Estimates